Search

• Preclinical data demonstrate sotrovimab retains activity against key Omicron mutations, new SARS-CoV-2 variant

  Media

  Data to be confirmed by further in vitro pseudo-virus testing

  https://www.gsk.com/en-gb/media/press-releases/preclinical-data-demonstrate-sotrovimab-retains-activity-against-key-omicron-mutations-new-sars-cov-2-variant/

  First published: 02 December 2021

• Preclinical studies demonstrate sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant

  Media

  New preclinical findings generated through in vitro testing of sotrovimab against the complete pseudo-virus, updated to bioRxiv

  https://www.gsk.com/en-gb/media/press-releases/sotrovimab-retains-activity/

  First published: 07 December 2021

• GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab, authorised for the early treatment of COVID-19

  Media

  600,000 additional doses to be supplied to the US Government for distribution in Q1 2022

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-united-states-government-agreement-to-purchase-additional-supply-of-sotrovimab/

  First published: 11 January 2022

• GlaxoSmithKline awarded up to $200 million by U.S. government to develop new antibiotics

  Media

  GSK & BARDA have agreed to support the development of several antibiotics to fight antibiotic resistance and bioterrorism.

  https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-awarded-up-to-200-million-by-us-government-to-develop-new-antibiotics/

  First published: 22 May 2013

• Results announcement for the fourth quarter 2016

  Media

  View full Q4 2016 Results (PDF)

  https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2016/

  First published: 08 February 2017

• GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA for treatment of mild-to-moderate COVID-19 in high-risk adults and paediatric patients

  Media

  GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-sotrovimab-vir-7831-receives-emergency-use-authorization-from-the-us-fda/

  First published: 26 May 2021

• Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

  Media

  Collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19.

  https://www.gsk.com/en-gb/media/press-releases/lilly-vir-biotechnology-and-gsk-announce-first-patient-dosed-in-expanded-blaze-4-trial/

  First published: 27 January 2021

• Lilly, Vir Biotechnology and GSK announce positive topline data from the phase 2 BLAZE-4 trial evaluating bamlanivimab with VIR-7831 in low-risk adults with COVID-19

  Media

  In combination, the 2 monoclonal antibodies demonstrated 70% relative reduction in persistent high viral load at day 7 compared to placebo.

  https://www.gsk.com/en-gb/media/press-releases/lilly-vir-biotechnology-and-gsk-announce-positive-topline-data-from-the-phase-2-blaze-4-trial-evaluating-bamlanivimab-with-vir-7831-in-low-risk-adults-with-covid-19/

  First published: 29 March 2021

• GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab

  Media

  U.S. National Institutes of Health (NIH) COVID-19 Treatment Guidelines updated to recommend use of sotrovimab.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-continuing-progress-of-the-comet-clinical-development-programme-for-sotrovimab/

  First published: 21 June 2021

• GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment

  Media

  US government contracts for approximately $1 billion (USD) now in place to purchase sotrovimab, further expanding access nationwide

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-united-states-government-agreements-to-purchase-sotrovimab-a-covid-19-treatment/

  First published: 17 November 2021